Genmab-developed sclerosis treatment beats competition in small injector pen study
Following the approval of sclerosis drug Kesimpta, originally from Genmab, Novartis is positioning this drug against its competitors. New study shows patients' and health personnel's impression of the firm's special injector pen compared with treatments from Teva, Biogen and Merck.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Novartis has, in a recent study, examined sclerosis patients' impressions of the firm's autoinjector pens used to administer its medication.
The recently approved drug Kesimpta has a high score in the survey.
Bavarian has been the center of attention in recent days due to its monkeypox vaccine, and the company has now secured a vaccine contract with another undisclosed country. Consequently, Bavarian has raised its expectations for the full year.